Participated · Series B · Aug 2026

Meduloc develops an FDA-cleared, sterile, single-use flexible nitinol intramedullary implant and delivery system for long-bone fracture applications in adult and pediatric patients. The platform is positioned to provide fracture stability while preserving anatomy and avoiding joint violation in certain applications. Following regulatory clearance, the company is moving into controlled commercialization and plans an alpha launch in early August 2026 with select surgeons and institutions to build clinical experience and collect feedback. Meduloc intends to use recently raised capital to generate additional clinical evidence and to build the commercial infrastructure required for broader adoption. The company is headquartered in West Chester, Pennsylvania, and has attracted regional investor support from Greater Philadelphia and statewide life-sciences funding organizations.

Participated · Series A · Feb 2026

Avisi Technologies, Inc. is a clinical-stage company focused on creating novel ophthalmic solutions, most notably VisiPlate®, an investigational aqueous shunt engineered from an ultrathin, patented metamaterial designed to maintain intra-ocular pressure through multiple microchannels that resist blockage and scarring. The device targets the unmet need for long-term, low-maintenance glaucoma care and is currently being evaluated in the FDA IDE-approved SAPPHIRE pivotal trial that is enrolling patients across the United States. Avisi’s broader pipeline includes V-001, a sustained intraocular drug-delivery platform, and VisiPlate-S, a drainage device intended for use during cataract surgery. Proceeds from its latest financing will fund the SAPPHIRE trial and advance additional pipeline programs addressing the full spectrum of glaucomatous disease. The company has garnered recognition and non-dilutive support from the National Science Foundation, the Glaucoma Research Foundation, Johnson & Johnson JLABS, and other industry accelerators. Current investors include both venture funds and angel networks, underscoring diversified backing for its development roadmap. No revenue or user figures have been disclosed to date.

Participated · Series D · Mar 2019

Micro Interventional Devices (MID) designs, develops and commercializes proprietary percutaneous technologies focused on structural heart disease. Its lead technology is MIA™ (Minimally Invasive Annuloplasty), intended for percutaneous treatment of tricuspid and mitral regurgitation. The company is completing the STTAR (Study of Transcatheter Tricuspid Annular Repair) clinical trial to evaluate MIA’s safety and efficacy. MID announced a strategic alliance with Oscor to further develop and commercialize solutions for structural heart disease. Under that alliance MID acquired a non-exclusive worldwide license to Oscor’s patented catheter technology while Oscor received exclusive manufacturing rights to MID’s MIA devices. The company is using the recent financing to complete its ongoing clinical study and advance commercialization efforts. Micro Interventional Devices (MID) is an emerging cardiovascular medical device company based in Bethlehem, PA, founded in May 2010. Its core product, Permaseal, is described as the first transapical access device to enable true "self-sealing," sutureless cardiac access and closure. Permaseal is designed to enable a range of structural heart repair procedures including transcatheter aortic valve implantation (TAVI) and mitral valve replacement and repair. MID is also developing percutaneous transapical and large bore femoral access and closure devices using proprietary soft-tissue anchoring technology that enables off-pump procedures. Financially, MID has secured $3.5M of an expected $5M Series B financing. The company intends to use the funding to advance Permaseal development, complete the STASIS clinical study, pursue CE Mark approval, and support ongoing R&D. Micro Interventional Devices is developing solutions for a wide range of structural heart repair procedures. The company is working on a new minimally invasive structural heart repair product called Permaseal™ and intends to use recent funding to develop and begin commercializing it. Micro Interventional Devices received a $100k loan from the Ben Franklin Technology Partners of Northeastern Pennsylvania. The company was founded in 2010 and is led by CEO Michael P. Whitman and CSO Willard Hennemann, PhD. Its development work targets procedures including TAVI, transcatheter mitral valve replacement, LVAD placement, mitral valve repair, valvuloplasty, aortic arch repair, ASD/VSD closure, left atrial appendage closure, and arrhythmia ablation. Micro Interventional Devices develops Permaseal, a sutureless closure device that uses soft tissue anchors and biocompatible elastomers to form a web structure around myocardial access sites and provide hemostatic left-ventricle access during minimally invasive cardiac procedures. The device is applied before transcatheter aortic valve implantation (TAVI) and constricts around the ventricular opening after guidewire extraction; the company is also pursuing use in transcatheter mitral valve replacement and mitral valve repair. The company was launched in 2010 in Bethlehem, Pennsylvania, and is pursuing CE-mark clinical evaluation (the STASIS study) and commercialization in Europe. A 40-person European STASIS trial scheduled for Q3 will evaluate safety and performance for left ventricular transapical access and closure, with procedure time as a secondary endpoint and top-line results expected in Q4. Financially, Micro Interventional Devices secured a $500,000 bridge financing earlier this year (with Life Sciences Greenhouse of Central Pennsylvania contributing) and counts Battelle Ventures, New Hope Ventures and Ben Franklin Technology Partners of Northeastern Pennsylvania among its investors. The company is commencing a Series B in September seeking $5–8 million to complete CE mark approval and support European commercialization. Micro Interventional Devices (MID) is an early-stage cardiovascular medical device company founded in May 2010 and located in Bethlehem, PA. MID's initial product offering is Permaseal, a patent-pending minimally invasive access and wound-closure device designed to move with the beating heart while keeping wound edges closed. Permaseal enables sutureless healing, and the company describes it as cost- and time-efficient for structural heart repair procedures. The device provides a biocompatible implant affixed to the apex of the heart to create a transmyocardial access site for procedures such as TAVI, transcatheter mitral valve replacement, mitral valve repair, LVAD placement, ASD/VSD closure, left atrial appendage closure and arrhythmia ablation. MID says its proprietary soft-tissue anchoring and delivery-device technology enables off-pump procedures and aims for Permaseal to become a new standard of care. Michael Whitman is named as President & CEO in the announcement.

Participated · Series D · Mar 2019

MacuLogix provides eye care professionals with the AdaptDx dark adaptometer to detect, monitor and treat age-related macular degeneration (AMD). Its flagship AdaptDx device can detect functional changes up to three years before AMD is visible clinically. The company also offers in-practice training and treatment best practices to support implementation and optimization of the AdaptDx. MacuLogix intends to use new funding to accelerate domestic and international sales through expansion of workforce and infrastructure. To date the company has raised a total of $51M in venture funding plus $10M in venture debt. The company is led by William D. McPhee, President and CEO, and Gregory R. Jackson, Ph.D., Chief Technology Officer. MacuLogix develops the AdaptDx automated dark adaptometer for eye care professionals to measure retinal function and accurately diagnose AMD. The company is led by President and CEO William D. McPhee. It is backed by investors including Roche Ventures, Fisk Ventures and Life Sciences Greenhouse of Central Pennsylvania. MacuLogix secured a $10M financing package in 2018 to support operations. Proceeds from the financing will be used for general working capital purposes. The company operates in the optometry and ophthalmology market from Middletown, PA. MacuLogix develops the AdaptDx, an automated dark adaptometer that measures dark adaptation to detect age-related macular degeneration (AMD) before vision loss. The AdaptDx is designed to enable eye care professionals to diagnose, monitor and treat AMD well before vision loss occurs by measuring a patient’s recovery of vision when going from daylight to darkness. The company says the technology can detect, monitor and treat AMD three years before it can be seen clinically and provides in-practice training and treatment best practices to support implementation and optimization. AMD affects more than 14 million Americans, and MacuLogix positions the AdaptDx as a tool to catch disease earlier when lifestyle changes and interventions may slow progression. Financially, the Life Sciences Greenhouse of Central Pennsylvania (LSGPA) has invested more than $2 million in the Middletown-based firm, including an additional $500,000 announced in the latest syndicate investment. LSGPA said the further investment reflects confidence from its co-investors and supports MacuLogix’s prospects for growth and job creation in central Pennsylvania. Maculogix has developed the AdaptDx device, a diagnostic tool that measures dark adaptation to detect age-related macular degeneration, retinitis pigmentosa and other macular diseases. The device is on the market and has received FDA 510(k) clearance. The test measures how the eye recovers after a mild photobleach, analogous to a cardiac stress test for vision. The company says the metric is useful for detecting early disease and tracking progression before patients notice symptoms. Maculogix has raised capital over time and, per SEC filings, has raised about $11.5 million since 2011. The company is based in Pennsylvania. The article notes the recent funding may be used to further market the already-approved device. MacuLogix develops AdaptDx™, a diagnostic tool intended for early detection and tracking of age-related macular degeneration (AMD). AdaptDx measures dark adaptation function and has received FDA 510(k) clearance for that measurement. Patient testing has been completed to support validation of AdaptDx as a diagnostic, though it is not currently cleared for sale as a diagnostic. The company plans to use new funding to accelerate manufacturing and commercial sales of AdaptDx to enable earlier intervention to prevent vision loss and improve quality of life. MacuLogix is based in Hummelstown, Pennsylvania and is led by CEO John G. Edwards. It recently completed a Series A financing to support these efforts.

Led · Seed · Feb 2018

Ocunova Inc. is an ophthalmic drug development company spun out of the Penn State College of Medicine. Its lead compound, OCU-001, is described as a rapid-acting, safe-to-use treatment targeting the underlying cause of diabetic Dry Eye Syndrome (DES). The company plans to use newly invested capital to advance development and conduct clinical trials of OCU-001. A joint investment of $500,000 was made by the Life Sciences Greenhouse of Central Pennsylvania and Ben Franklin Technology Partners/CNP to support these efforts. The article highlights the unmet need—up to 50% of patients with diabetes may have DES and more than three million U.S. diabetic patients experience chronic dry eye—and notes there are no treatments approved specifically for diabetic DES. Ocunova was founded by local entrepreneurs based on Penn State research and is positioning OCU-001 as a novel approach compared with temporary over-the-counter drops or existing anti-inflammatory prescriptions that have delayed onset and side effects.